Together, WashU Medicine and Siteman Cancer Center have long been a powerhouse in cancer research and a national leader in providing innovative, compassionate care to patients while pushing the boundaries of what’s possible in treating this ancient and ever-evolving disease. Our researchers and clinicians are poised to shape future decades of cancer advances after having […]
Tycel Phillips, MD, questioned how the regimen of acalabrutinib, bendamustine, and rituximab would compare with taking the drugs separately in mantle cell lymphoma.
The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Happy New Year! We hope that keeping your skin safe and healthy is one of your goals for 2025. Here are three easy ways to…
SAN DIEGO — The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than reported in prior clinical…
The phase 3 MECCA trial represents the largest data set investigating the efficacy of metronomic chemo-endocrine combination therapy in metastatic breast cancer, according to researchers.
Register now for HMD 2025 and explore groundbreaking advancements in hematology. Stay informed with the latest innovations shaping the future of hematology research presented at…
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.
W. Kimryn Rathmell has stepped down as NCI director, opting to hand her resignation to the Biden administration over facing the uncertainties that Trump and…
The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.
